An FDA panel has given a go-ahead to diabetes drug Avandia, which has been widely linked to the risks of developing heart ailments in consumers. However, it clarified that the supply of the drug will be kept under extreme scrutiny in the market.
The advisory panel made the suggestions on Wednesday, saying the drug will be carrying the warnings regarding the side effects it carries.
The recommendations of the panel have added to the concerns over the use of the drug as the professionals are thinking twice before prescribing Avandia for the treatment of type-II diabetes.
In addition, the voting observed in the panel has disappointed GlaxoSmithKline, Avandia’s producer, as the sales are likely to get reduced.
The panel claimed that the company has been hiding the side effects of the drug for over a year from the people.
Avandia, called rosiglitazone, is essentially used for reducing the sugar levels in the blood and, thereby, increasing the sensitivity of the body to insulin.
Over the past few years, the healthcare professionals have shown a reduced trust on the safety of the drug, as more and more substantiations on the drug’s side effects kept emerging.